Joanne Neale1, Adrian Farrugia2, Aimee N Campbell3, Paul Dietze4, Robyn Dwyer5, Renae Fomiatti2, Jermaine D Jones3, Sandra D Comer3, Suzanne Fraser2, John Strang1. 1. National Addiction Centre, King's College London, London, UK. 2. Australian Research Centre in Sex, Health and Society, La Trobe University, Melbourne, Australia. 3. Division on Substance Use Disorders, Department of Psychiatry, New York State Psychiatric Institute and Columbia University Irving Medical Center, New York, USA. 4. Program on Behaviours and Health Risks, Burnet Institute, Melbourne, Australia. 5. Centre for Alcohol Policy Research, School of Psychology and Public Health, La Trobe University, Melbourne, Australia.
Abstract
Background: Take-home naloxone (THN) is provided to non-medically trained people to reverse potential opioid overdoses. There is an increasing range of effective intramuscular (IM) and intranasal (IN) naloxone devices and this paper explores the types preferred by people who use opioids, using consumer behaviour literature to interpret the findings. Methods: Data derive from two unconnected qualitative studies involving audio-recorded semi-structured interviews. Study 1 was conducted in the United States (n=21 users of non-medical/illicit opioids). Study 2 was conducted in Australia (n=42 users of non-medical/illicit or prescribed opioids). Findings: Most participants preferred IN naloxone. Preferences were based on the ease, speed, safety and comfort of each device and underpinned by accounts of overdose revivals as being very rushed and frightening situations. Preferences related to complex interactions between the naloxone device ('product'); the knowledge, skills, experience and attitudes of the lay responder ('consumer'), and when, where and how naloxone was to be used ('usage situation'). Conclusions: THN programs should offer choice of device when possible and nasal naloxone if resources permit. Asking people which devices they prefer and why and treating them as valued consumers of naloxone products can generate insights that improve future naloxone technology and increase THN uptake and usage.
Background: Take-home naloxone (THN) is provided to non-medically trained people to reverse potential opioid overdoses. There is an increasing range of effective intramuscular (IM) and intranasal (IN) naloxone devices and this paper explores the types preferred by people who use opioids, using consumer behaviour literature to interpret the findings. Methods: Data derive from two unconnected qualitative studies involving audio-recorded semi-structured interviews. Study 1 was conducted in the United States (n=21 users of non-medical/illicit opioids). Study 2 was conducted in Australia (n=42 users of non-medical/illicit or prescribed opioids). Findings: Most participants preferred IN naloxone. Preferences were based on the ease, speed, safety and comfort of each device and underpinned by accounts of overdose revivals as being very rushed and frightening situations. Preferences related to complex interactions between the naloxone device ('product'); the knowledge, skills, experience and attitudes of the lay responder ('consumer'), and when, where and how naloxone was to be used ('usage situation'). Conclusions: THN programs should offer choice of device when possible and nasal naloxone if resources permit. Asking people which devices they prefer and why and treating them as valued consumers of naloxone products can generate insights that improve future naloxone technology and increase THN uptake and usage.
Authors: Barbara R Cohen; Karen M Mahoney; Elande Baro; Claudia Squire; Melissa Beck; Sara Travis; Amanda Pike-McCrudden; Rima Izem; Janet Woodcock Journal: N Engl J Med Date: 2020-05-28 Impact factor: 91.245
Authors: Joanne Neale; Caral Brown; Aimee N C Campbell; Jermaine D Jones; Verena E Metz; John Strang; Sandra D Comer Journal: Addiction Date: 2018-12-28 Impact factor: 6.526
Authors: Arne Kristian Skulberg; Anders Åsberg; Hasse Zare Khiabani; Hilde Røstad; Ida Tylleskar; Ola Dale Journal: Addiction Date: 2019-02-15 Impact factor: 6.526